Ann: Research partnership with Celularity for solid tumors, page-14

Imugene is partnering with another research phase company. It looks like a good match - combining OnCARlytics with a next generation CAR-T. Just don't expect immediate $$ to flow from this - it's a longer term project with no revenue in the short term.

It continues Imugene's strategic path of broadening their IP and product base - with a partner who will probably do a lot of the work - further derisking Imugene. This is just one direction for OnCARlytics - and it could be very successful. I expect Imugene will end up with several partners for further development of OnCARlytics.

Another good move on the Biotech chessboard. Plenty more to come, and the money will follow in due course.

Cheers

Dave